Topic: Advances in Precision Medicine for HCC
A Special Issue of Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)
Submission deadline: 1 Sep 2024
Guest Editor(s)
Special Issue Introduction
Despite advances in the treatment of hepatocellular carcinoma (HCC), the prognosis of HCC remains poor. Recent advancements in integrative genomic studies have revealed distinct genomic alterations in HCC, affecting cell cycle regulation, DNA damage and repair, kinase signaling, and morphogenic processes. These variations significantly differ among various subtypes of HCC, adding further complexity to understanding and managing this disease. Additionally, epigenetic mechanisms, including methylation deregulation, histone modifications, abnormal expression of non-coding RNAs, and post-translational modifications of proteins, have been demonstrated to play pivotal roles in both the initiation and progression of HCC.
In this Special Issue of Hepatoma Research, leading experts will explore the complex genetic and epigenetic disturbances that underpin HCC. They will examine the interactions among cells within the tumor microenvironment, as well as the molecular effectors and associated signaling pathways that promote HCC’s malignancy and invasiveness. These discussions will shed light on the latest strides in precision medicine for HCC, with a focus on crafting targeted therapies, immunotherapeutic strategies, and personalized treatment plans tailored to the genomic and epigenomic profiles of individual patients.
Potential topics include, but are not limited to, the following:
1. Genetic predisposition involved in HCC development;
2. Mutational signatures and HCC development;
3. Molecular classifications of HCC;
4. Personalizing treatment through functional assays;
5. Integrative analysis of genetic and epigenetic features and their correlation with clinical and pathological features of HCC;
6. Biomarker-driven clinical trials;
7. Dissection of HCC microenvironment to inform immunotherapy response;
8. Biomarker-driven preclinical molecular and immune checkpoint blockade therapies;
9. Biomarkers of response to systemic therapy;
10. Integrative classification revealing subclass-specific drug response.
In this Special Issue of Hepatoma Research, leading experts will explore the complex genetic and epigenetic disturbances that underpin HCC. They will examine the interactions among cells within the tumor microenvironment, as well as the molecular effectors and associated signaling pathways that promote HCC’s malignancy and invasiveness. These discussions will shed light on the latest strides in precision medicine for HCC, with a focus on crafting targeted therapies, immunotherapeutic strategies, and personalized treatment plans tailored to the genomic and epigenomic profiles of individual patients.
Potential topics include, but are not limited to, the following:
1. Genetic predisposition involved in HCC development;
2. Mutational signatures and HCC development;
3. Molecular classifications of HCC;
4. Personalizing treatment through functional assays;
5. Integrative analysis of genetic and epigenetic features and their correlation with clinical and pathological features of HCC;
6. Biomarker-driven clinical trials;
7. Dissection of HCC microenvironment to inform immunotherapy response;
8. Biomarker-driven preclinical molecular and immune checkpoint blockade therapies;
9. Biomarkers of response to systemic therapy;
10. Integrative classification revealing subclass-specific drug response.
Submission Deadline
1 Sep 2024
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/hr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=hr&SpecialIssueId=hr240428
Submission Deadline: 1 Sep 2024
Contacts: Eric Zhang, Assistant Editor, scienceeditor@hrpublishing.net
